PITTSBURGH, June 18 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. announced today that the quarterly cash dividend of $0.06 per share will be payable on July 16, 2007, to shareholders of record at the close of business on June 29, 2007.
Mylan previously stated that in conjunction with the announced acquisition of Merck KGaA’s generic business, Mylan is suspending the dividend on its common stock. The suspension is effective immediately following payment of this quarterly dividend.
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.
For more information about Mylan, visit www.mylan.com.
Mylan Laboratories Inc.
CONTACT: Patrick Fitzgerald or Kris King of Mylan Laboratories Inc.,+1-724-514-1800
Web site: http://www.mylan.com//
